Does combination therapy with paricalcitol and enalapril ameliorate cardiac oxidative injury in uremic rats?
Enalapril, paricalcitol and their combined therapy afford protection against cardiac oxidative stress in uremia.
These results indicate that, similar to SMA, the SMN2 gene can act as a prognostic factor and may therefore be a phenotypic modifier in sporadic ALS. Increasing the expression of the SMN2 gene may provide a strategy for treatment of motor neuron disease.